2024
Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States
Park H, Gonsalves G, Tan S, Kelly J, Rutherford G, Wachter R, Schechter R, Paltiel A, Lo N. Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States. Nature Communications 2024, 15: 1883. PMID: 38448400, PMCID: PMC10917753, DOI: 10.1038/s41467-024-45549-9.Peer-Reviewed Original ResearchConceptsSevere COVID-19Risk of severe COVID-19COVID-19 booster vaccinationBooster vaccinationHigh-risk populationAbsolute annual riskWaning of protectionImmunocompromised populationsFrequent boostingOlder age groupsAnnual boosterImmune evasionImmunocompromised personsPublic health needsPublic health guidanceRisk groupsFrequent boostersImmune statusRisk factorsFrequency of booster vaccinationHealth needsHealth guidanceCompare frequenciesAge groupsVaccine
2021
Assessing COVID-19 Prevention Strategies to Permit the Safe Opening of Residential Colleges in Fall 2021
Paltiel AD, Schwartz JL. Assessing COVID-19 Prevention Strategies to Permit the Safe Opening of Residential Colleges in Fall 2021. Annals Of Internal Medicine 2021, 174: m21-2965. PMID: 34461034, PMCID: PMC8422997, DOI: 10.7326/m21-2965.Peer-Reviewed Original ResearchConceptsVaccine effectivenessVaccination coverageAsymptomatic testingBroad vaccination coverageLess frequent testingCOVID-19 prevention strategiesHigh vaccination ratesBase-case assumptionsFall 2021COVID-19 incidenceUnvaccinated personsVaccination ratesDisease progressionHypothetical cohortEffective vaccineAsymptomatic transmissionPrevention strategiesViral transmissionCumulative casesNonpharmaceutical interventionsDrug abuseCumulative infectionsSafe returnVaccinePopulation coverage
2020
Clinical Outcomes Of A COVID-19 Vaccine: Implementation Over Efficacy
Paltiel AD, Schwartz JL, Zheng A, Walensky RP. Clinical Outcomes Of A COVID-19 Vaccine: Implementation Over Efficacy. Health Affairs 2020, 40: 42-52. PMID: 33211536, PMCID: PMC7931245, DOI: 10.1377/hlthaff.2020.02054.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccineVaccine efficacyCoronavirus disease 2019 (COVID-19) vaccinesSignificant vaccine hesitancyClinical outcomesClinical trialsVaccination programVaccine hesitancyEpidemic severityVaccineAuthorized vaccinesHealth officialsCumulative infectionsEfficacyVaccine productionDistribution programSeverityOutcomesUrgent needHospitalizationVaccinationInfectionTrialsGlobal efforts
2011
The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: Examining the RV144 trial results
Andersson KM, Paltiel AD, Owens DK. The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: Examining the RV144 trial results. Vaccine 2011, 29: 6107-6112. PMID: 21736912, PMCID: PMC3164284, DOI: 10.1016/j.vaccine.2011.06.076.Peer-Reviewed Original ResearchConceptsBooster vaccinationHIV prevalencePopulation coverage levelsRV144 trialHIV vaccineCondom useContinuous vaccinationHIV vaccine regimenPopulation HIV prevalenceDuration of protectionCoverage levelsRV144 vaccineVaccine regimenHIV infectionHeterosexual transmissionModest efficacyVaccine efficacyUnvaccinated populationVaccination strategiesPartial efficacyEfficacy vaccineLower riskVaccinationBooster strategyVaccine
2007
Predicting the Impact of a Partially Effective HIV Vaccine and Subsequent Risk Behavior Change on the Heterosexual HIV Epidemic in Low- and Middle-Income Countries
Andersson KM, Owens DK, Vardas E, Gray GE, McIntyre JA, Paltiel AD. Predicting the Impact of a Partially Effective HIV Vaccine and Subsequent Risk Behavior Change on the Heterosexual HIV Epidemic in Low- and Middle-Income Countries. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2007, 46: 78-90. PMID: 17589368, PMCID: PMC3570247, DOI: 10.1097/qai.0b013e31812506fd.Peer-Reviewed Original ResearchConceptsEffective HIV vaccineHIV prevalenceHIV vaccineCondom useHIV infectionRisk behaviorsFuture HIV prevalenceTotal HIV infectionsHeterosexual HIV epidemicSuccessful vaccination campaignsRisk behavior changeVaccination statusMiddle-income countriesVaccinated individualsVaccination coverageDisease stageVaccine efficacyHIV epidemicVaccination scenariosVaccination campaignHigh riskAdult populationVaccinePrevalenceInfection
2004
A therapeutic HIV vaccine: how good is good enough?
Walensky RP, Paltiel AD, Goldie SJ, Gandhi RT, Weinstein MC, Seage GR, Smith HE, Zhang H, Freedberg KA. A therapeutic HIV vaccine: how good is good enough? Vaccine 2004, 22: 4044-4053. PMID: 15364455, DOI: 10.1016/j.vaccine.2004.03.059.Peer-Reviewed Original Research